Clinical trial Recruiting at 6 sites Observational Ages 18 and up

Registry of Resorbable Magnesium Scaffolds for Coronary Artery Disease

Official title: RMS (Resorbable Magnesium Scaffolds) Registry

Run by Biotronik AG · NCT04679740 · Data updated 2026-11-12

This study is testing how well resorbable magnesium scaffolds work and if they are safe for people with coronary artery disease.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1106 (estimated)
SponsorBiotronik AG
Industry-sponsored
Locations13 sites (Cairns and 12 other locations)
StatusRecruiting
StartedNovember 18, 2020
Main results expectedMay 2030
Study endsMay 2030
Registry record updatedNovember 21, 2025
Trial IDNCT04679740 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this registry are patients diagnosed with coronary artery disease who are eligible for treatment with resorbable magnesium scaffolds according to the instructions for use.

Probably not a fit

Patients who do not meet the inclusion criteria or have contraindications as per the instructions for use may not benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to evaluate the clinical performance and short-term safety of resorbable magnesium scaffolds (RMS) in patients with coronary artery disease. It follows the guidelines set by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery, collecting real-world data on the use of Magmaris scaffolds. The study includes patients who meet the instructions for use without additional exclusion criteria, allowing for a broad assessment of the device's effectiveness in a clinical setting.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the safety and efficacy of resorbable magnesium scaffolds, potentially improving treatment options for patients with coronary artery disease.

How similar studies have gone: While this registry approach is not novel, similar studies have shown promising results in evaluating the safety and effectiveness of resorbable scaffolds in coronary interventions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* According to the IFU

Exclusion Criteria:

* According to the IFU

Where it's running

  • Heart Center Segeberger Kliniken
    Bad Segeberg, Germany
    Recruiting
  • Centro Cardiologico Monzino
    Milan, Lombardy, Italy
    Recruiting
  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ w Lublinie
    Lublin, Poland
    Recruiting
  • Lindenhofspital
    Bern, Switzerland
    Recruiting
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, Switzerland
    Recruiting
  • Solothurner Spitäler AG
    Olten, Switzerland
    Recruiting
Show 7 more locations
  • Cairns Hospital
    Cairns, Australia
    Completed
  • Krankenhaus Buchholz
    Buchholz, Germany
    Completed
  • Klinikum Westfalen, Knappschaft KH
    Dortmund, Germany
    Completed
  • Klinikum Herford
    Herford, Germany
    Completed
  • Herz-und Gefäßzentrum Oberallgäu-Kempten
    Kempten, Germany
    Completed
  • Daugavpils Regional Hospital
    Daugavpils, Latvia
    Completed
  • SUSCCH Banska Bystrica
    Banská Bystrica, Slovakia
    Completed

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.